期刊
DERMATOLOGIC SURGERY
卷 42, 期 11, 页码 S275-S281出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/DSS.0000000000000875
关键词
-
资金
- Kythera Biopharmaceuticals, Inc.
- Kythera Biopharmaceuticals, Inc. (an affiliate of Allergan plc, Dublin, Ireland)
- Allergan plc, Dublin, Ireland
ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) is the first aesthetic injectable approved for reduction of submental fat. In February 2014, an injection practicum was conducted in the anatomy laboratory at the University of Texas Southwestern Medical Center to explore the proper injection technique for ATX-101 and the importance of its appropriate, safe anatomical placement within the submental area. Subsequent to the injection practicum, a structured roundtable discussion was conducted in which potential implications of the various injection protocols evaluated during the practicum were reviewed. Furthermore, the faculty had the opportunity to provide additional perspectives based on their clinical experience with facial injectables and ATX-101 specifically. In this article, the findings from the injection practicum and roundtable discussion are reported.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据